Home About Us Pipeline News Investors Contacts Careers

STOCK INFORMATION

UPCOMING EVENTS

There are no scheduled events at this time. Please check back later.

FEATURED PRESS RELEASE

  • 11/13/17 3:34 pm PST

    Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma’s drug neratinib in patients with early stage HER2-positive breast cancer in the journal The Lancet Oncology. The article, entitled “Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer (ExteNET): 5-year analysismore...

SEARCH INVESTOR RELATIONS

CONTACTS

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

ir@pumabiotechnology.com